Stem cells are primitive cells found in all multi-cellular organisms that are characterized by self-renewal and the capacity to differentiate into any mature cell type.
Stem cells are still a relatively new discovery, as the first mouse embryonic stem cells were derived from embryos in 1981, but it was not until 1995 that the first successful culturing of embryonic stem cells from non-human primates occurred and not until November 1998 that a technique was developed to isolate and grow embryonic stem cells from human blastocysts. In 2006, induced pluripotent stem cells were produced for the first time from mouse cells and in 2007 they were produced from human cells. Furthermore, it was not until 2008 that the first full transplant of a human organ grown from adult stem cells was performed when a section of trachea was successfully transplanted into an adult woman in Spain.
The past 10 years have also witnessed the production of novel stem cell types, including piPSCs, R-NSCs, and VSELs. Together, this evidence suggests that additional types of stem cells will likely be discovered, each representing new opportunities for research product development. Clearly, laboratory research into stem cell derivation, manipulation, and application is rapidly expanding.
To facilitate research resulting from these advances, a large and diverse stem cells products market has emerged. Large companies selling stem cell research products include Thermo Fisher Scientific (now merged with Life Technologies), BD Biosciences, EMD Millipore, Sigma Aldrich, and STEMCELL Technologies, as well as over one hundred other suppliers.
Furthermore, to sell products in the stem cell market, it is critical to understand the research applications for which stem cells are being studied. One area of study is the use of stem cells to understand and treat birth disorders. However, of greater interest to researchers is the potential for use of stem cells in regenerative medicine to treat conditions ranging from diabetes, to cardiovascular disease and neurological disorders.
Pharmaceutical companies have intense interest in the ability to use stem cells to improve drug target validation and toxicology screening. Therefore, it is important for companies interested in stem cell therapy applications to understand underlying market forces, and in particular, to consider progressive areas of stem cell research as opportunistic areas for drug and therapy development. This report presents a range of topics of interest to these companies as well, including how advances in stem research can reveal potential new drug targets, improve methods of drug delivery, and provide personalized treatment strategies.
This 2014 report provides detailed information on both basic and applied stem cell research and research applications and includes an updated list of global stem cell research centers by region.
Furthermore, it is crucial for stem cell companies to understand the funding environment that supports stem cell research. Currently, the U.S. federal government is an important, although not dominant, source of funding for stem cell research. The reason is that U.S. states are spending almost as much as the federal government on stem cell research and are actually spending more than the federal government on human embryonic stem cell (hESC) research. Private sources also contribute a huge amount of funding, with analysis of recent large gifts summing to over $1.7 billion.
Growth in stem cell research has exploded in the past decade, and so the market to supply stem cell research products has grown to meet this huge demand. There are now over one million stem cell researchers worldwide. In addition, there were only 17 stem cell product companies as of 2006, and that has expanded to more than 100 today, a 6-fold increase.
The two most active areas of stem cell research are mesenchymal stem cells, at 24.8% of all stem cell research, and hematopoietic stem cells, at 24.1% - thus accounting for nearly half of all stem cell research over a trailing twelve-month period. When this analysis was last conducted using data from full-year 2012 (Jan 1, 2012 - Dec 31, 2012), hematopoietic stem cell research led mesenchymal stem cell research, but that relationship has since switched, revealing an interesting preference toward mesenchymal stem cell research among the scientific community.
Also of interest is that for the trailing-twelve months, induced pluripotent stem cell research activity represented 8.9% of global stem cell research activity. When this analysis was last conducted using full-year 2012 data (Jan 1, 2012 - Dec 31, 2012), induced pluripotent stem cell research activity represented only 4.0% of global research activity, which means that a substantial year-over-year shift has occurred. This report explores why this trend has developed and how it will continue to evolve in the coming decade.
Not surprisingly, trend analysis reveals rapid increases in stem cell research activity over the past five years, specifically a scientific publication rate increase of 9.9% per year.
While hematopoietic stem cells represent the second most active area of stem cell research, publication rates for these stem cell types have declined in recent years. Because research activity by stem cell type has shown divergent trends over the past few years, for research product companies to be successful, they will need to understand underlying trends in stem cell preferences, by cell type.
This market intelligence report will advantageously position your company to offer competitive stem cell products to a rapidly growing, well-funded research community.
A key element of this report is a survey of stem cell researchers, for the U.S. and worldwide. This 2014 survey reveals stem cell researcher needs, technical preferences, key factors influencing buying decisions, and more. It can be used to make effective product development decisions, create targeted marketing messages, and produce higher prospect-to-client conversion rates.
To benefit from this lucrative product market, you need to anticipate and serve the needs of your clients, or your competitors will.
This survey reveals critical findings that include:
There is conclusive evidence that entering the stem cell research products market is financially worthwhile. Full-year 2013 analysis determines the size of the stem cell research products market to be $3.22 billion, and the stem cell therapies market to be $3.31 billion, for a total of $6.53 billion. In addition, both markets are growing with double-digit growth. Producing stem cell research products thus represents a massive profit opportunity for research supply companies.
Additionally, the industry insights contained in this market report will allow you to dramatically increase your profits within the stem cell sector.
Key findings within the report include:
Producing stem cell products can involve complicated and confusing decisions, but it doesn't have to. Claim this report to reveal the current and future needs of your customer base, so you can focus your marketing efforts on the most profitable products, in the most promising research areas and within the most lucrative domestic and international markets.
Your competitors would prefer you didn't buy this report. But when you do, you'll be gaining invaluable stem cell market insights to help you control and dominate this market.
Stem Cell Publications by Year
(Search Terms = "Stem Cell" or "Stem Cells")
Browse more Regenerative Medicine Market Research Reports